Cancer-Code CorporationCancer-Code CorporationThe dawn of a new approach to cancer treatmentThe dawn of a new approach to cancer treatment

The unfortunate realities of The unfortunate realities of cancercancer

New cancer cases will jump to 22 million cases New cancer cases will jump to 22 million cases annually in the next two decadesannually in the next two decades

-USA Today, Feb. 4, 2014-USA Today, Feb. 4, 2014-USA Today, Feb. 4, 2014-USA Today, Feb. 4, 2014

It is well known that chemotherapy and radiation treatments It is well known that chemotherapy and radiation treatments cause sickness, pain, disfigurement, depression, baldness, cause sickness, pain, disfigurement, depression, baldness,

and are often ineffective. and are often ineffective.

Cancer-Code Cancer-Code Corporation (C³)Corporation (C³)

A bioelectronic A bioelectronic medical approach to medical approach to

cancer treatment cancer treatment A bioelectronic A bioelectronic

medical approach to medical approach to cancer treatment cancer treatment

A bioelectronic A bioelectronic medical approach to medical approach to

cancer treatment cancer treatment C³ expects to determine the C³ expects to determine the

electrical codes for lung, prostate electrical codes for lung, prostate and breast cancers during an initial and breast cancers during an initial

Phase 1 six (6) month demonstration Phase 1 six (6) month demonstration period and many additional cancers period and many additional cancers

during a follow-on six (6) months.during a follow-on six (6) months.

C³ intends to establish itself as the leading champion C³ intends to establish itself as the leading champion for the newly emerging field of cancer cell for the newly emerging field of cancer cell communication signaling medicine in its dynamic quest communication signaling medicine in its dynamic quest to reduce the cancer death rate and improve the to reduce the cancer death rate and improve the survival rate, while lowering the cost of cancer survival rate, while lowering the cost of cancer treatments and medical therapy. treatments and medical therapy.

C³ is seeking funding for initial animal studies and C³ is seeking funding for initial animal studies and commercialization effortscommercialization efforts

The ObjectivesThe Objectives

The TechnologyThe Technology• The application of ultra-low voltage signals to target cancer cells and The application of ultra-low voltage signals to target cancer cells and

trigger and cause cellular suicide (apoptosis). trigger and cause cellular suicide (apoptosis).

• The treatment signals are very tiny and mimic the power levels found The treatment signals are very tiny and mimic the power levels found naturally in cancerous cells. naturally in cancerous cells.

• No chemotherapy or radiation is used No chemotherapy or radiation is used

• The technology takes advantage of the fact that the malignant cells in the The technology takes advantage of the fact that the malignant cells in the tumor are linked together and thus, will spread the signals within the tumor. tumor are linked together and thus, will spread the signals within the tumor.

• C³'s effort is to demonstrate the rapid killing of human breast, prostate and C³'s effort is to demonstrate the rapid killing of human breast, prostate and lung cancer cells, which are implanted on the backs of laboratory rodents lung cancer cells, which are implanted on the backs of laboratory rodents and commercialize products based on our studies. and commercialize products based on our studies.

• Pathology examinations or evaluations will scientifically verify the results of Pathology examinations or evaluations will scientifically verify the results of our approach. our approach.

Business ModelBusiness Model

• C³ is a for-profit corporation and will commercialize or license C³ is a for-profit corporation and will commercialize or license commercial rights to manufacture and market C³ products (initially commercial rights to manufacture and market C³ products (initially a hybrid computerized neuro-electric technology platform about a hybrid computerized neuro-electric technology platform about the size of a domino, configured with treatment codes and ancillary the size of a domino, configured with treatment codes and ancillary products) to kill selected cancers. products) to kill selected cancers.

• C³ would expect revenues/royalties income from this ultra-low C³ would expect revenues/royalties income from this ultra-low voltage commercial product line, which would evolve from such voltage commercial product line, which would evolve from such arrangement. arrangement.

• The marketable products would be compact in size and offered to The marketable products would be compact in size and offered to hospitals, cancer research institutes, university medical schools hospitals, cancer research institutes, university medical schools and treatment facilities and veterinarian hospitals or veterinarians. and treatment facilities and veterinarian hospitals or veterinarians.

• There is no known competitive medical technology; not even close! There is no known competitive medical technology; not even close!

U.S. Patent No. 8,656,930 - “Method and System U.S. Patent No. 8,656,930 - “Method and System for Processing Cancer Cell Electrical Signals for for Processing Cancer Cell Electrical Signals for Medical Therapy,”Medical Therapy,”

U.S. Patent No. 8,315,712 - “Hybrid Scientific U.S. Patent No. 8,315,712 - “Hybrid Scientific Computer System for Processing Cancer Cell Computer System for Processing Cancer Cell Signals as Medical Therapy”Signals as Medical Therapy”

U.S. Patent Application Serial No. 12/334,212 - U.S. Patent Application Serial No. 12/334,212 - “Method to Switch-Off Cancer Cell Electrical “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.Communication Codes as Medical Therapy”.

U.S. Patent Application Serial No. 12/936,778 - U.S. Patent Application Serial No. 12/936,778 - “System and Method to Elicit Apoptosis in “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.Malignant Tumor Cells for Medical Therapy”.

U.S. Patent Application Serial No. 14/182,417 - U.S. Patent Application Serial No. 14/182,417 - “Method and System for Processing Cancer Cell “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”Electrical Signals for Medical Therapy”

U.S. Provisional Application filed February 14, U.S. Provisional Application filed February 14, 2014 - “Encoded Bioelectronic Method and 2014 - “Encoded Bioelectronic Method and System for Slaying Cancer by Rapid Triggering System for Slaying Cancer by Rapid Triggering of Cellular Apoptosis and Karyorrhexis” [of Cellular Apoptosis and Karyorrhexis” [Patent Patent title edited for confidentialitytitle edited for confidentiality]]

Intellectual Intellectual PropertyProperty

Additional patents will be filed in 2014 Additional patents will be filed in 2014 including priority for new foreign including priority for new foreign

rightsrights

Competitive LandscapeCompetitive Landscape

Noteworthy - GSK (GlaxoSmithKline) - announced in 2013 an Noteworthy - GSK (GlaxoSmithKline) - announced in 2013 an unprecedented effort to develop bioelectronics as the “medicine of the unprecedented effort to develop bioelectronics as the “medicine of the future”. GSK, which is Britain’s largest drug maker, hopes to have the first future”. GSK, which is Britain’s largest drug maker, hopes to have the first medicine that “speaks the electrical language of the [human] body ready medicine that “speaks the electrical language of the [human] body ready for approval by 2020”. What GSK lacks, however, is the intellectual for approval by 2020”. What GSK lacks, however, is the intellectual property rights in this area, particularly in the field of bioelectronic property rights in this area, particularly in the field of bioelectronic medicines for cancer treatment. medicines for cancer treatment.

C³C³ is currently the only licensee with rights to is currently the only licensee with rights to develop and commercialize the IPdevelop and commercialize the IP

117 Bryn Mawr Dr SE117 Bryn Mawr Dr SE

Albuquerque, NM 87106Albuquerque, NM 87106

info@info@cancercodecorpcancercodecorpcancercodecorp.comcancercodecorp.com

505-314-1311505-314-1311

oror

505-314-1312505-314-1312

117 Bryn Mawr Dr SE117 Bryn Mawr Dr SE

Albuquerque, NM 87106Albuquerque, NM 87106

info@info@cancercodecorpcancercodecorpcancercodecorp.comcancercodecorp.com

505-314-1311505-314-1311

oror

505-314-1312505-314-1312